NCT05233436
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: To be eligible for Part 1B (Combination Therapy) or Part 2 (Dose Expansion), breast cancer patients must have progressed on systemic anticancer therapies, including at least 1 checkpoint inhibitor (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with central nervous system metastases; Patients with prior administration of HPK1 inhibitor
https://ClinicalTrials.gov/show/NCT05233436